Contineum Therapeutics (NASDAQ:CTNM) Upgraded to Strong-Buy at Leerink Partnrs

Key Points

• Contineum Therapeutics has been upgraded to a "strong-buy" rating by Leerink Partners, indicating growing confidence among analysts.
• The company's stock shows a consensus target price of $22.20, with multiple analysts assigning "buy" ratings.
• Contineum's recent earnings report showed a loss of ($0.62) per share, which was below analysts' expectations of ($0.56).

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs to a "strong-buy" rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other analysts have also recently weighed in on the stock. William Blair began coverage on shares of Contineum Therapeutics in a report on Friday, June 20th. They set an "outperform" rating for the company. Leerink Partners began coverage on shares of Contineum Therapeutics in a research note on Thursday. They issued an "outperform" rating and a $20.00 price objective for the company. Finally, Morgan Stanley raised their price objective on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $22.20.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $10.86 on Thursday. The stock has a market capitalization of $304.51 million, a price-to-earnings ratio of -4.94 and a beta of 1.19. Contineum Therapeutics has a 1-year low of $3.35 and a 1-year high of $20.24. The company has a 50 day moving average price of $8.89 and a 200 day moving average price of $6.18.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). On average, sell-side analysts expect that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new position in Contineum Therapeutics in the 1st quarter worth $27,000. Qube Research & Technologies Ltd acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $43,000. Marex Group plc acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $45,000. Bridgeway Capital Management LLC acquired a new position in Contineum Therapeutics in the second quarter valued at about $76,000. Finally, Jane Street Group LLC acquired a new position in Contineum Therapeutics in the second quarter valued at about $81,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.